StocksMediumUpdated•Originally published 4 November 2026•Updated 4 November 2026•
1 min read
Nuvation Bio Q3 Revenue of $45 Million Beats Consensus Estimates
Key Facts
1Nuvation Bio achieved $45.0 million in total revenue for the third quarter of 2026.
2IBTROZI net product revenue reached $27.5 million, with a label update reflecting a median duration of response of 49.7 months.
3The company held cash, cash equivalents, and marketable securities of $663.4 million as of September 30, 2026.
Nuvation Bio reported total revenue of $45.0 million for the third quarter of 2026, exceeding the FactSet consensus estimate of $34.4 million. According to a company statement, net product sales for IBTROZI reached $27.5 million during the period, significantly contributing to the top-line beat.
The company maintained cash, cash equivalents, and marketable securities totaling $663.4 million as of September 30, 2026, to fund its clinical development pipeline. Nuvation Bio also updated the IBTROZI label to reflect a median duration of response of 49.7 months, while shares of NUVB closed at $4.69 on November 3, 2026.